Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:789353.
doi: 10.1155/2014/789353. Epub 2014 Nov 6.

A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogs

Affiliations

A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogs

Ana Paula Prados et al. Vet Med Int. 2014.

Abstract

This study was conducted in order to characterize the pharmacokinetics of orally administered cephalexin to healthy adult and aged dogs, using a population pharmacokinetic approach. Two hundred and eighty-six cephalexin plasma concentrations obtained from previous pharmacokinetic studies were used. Sex, age, pharmaceutical formulation, and breed were evaluated as covariates. A one-compartment model with an absorption lag-time (Tlag) best described the data. The final model included age (adult; aged) on apparent volume of distribution (Vd/F), apparent elimination rate (ke/F), and Tlag; sex (female; male) on ke/F, and breed (Beagle; mixed-breed) on Vd/F. Addition of the covariates to the model explained 78% of the interindividal variability (IIV) in Vd/F, 36% in ke/F, and 24% in Tlag, respectively. Formulation did not affect the variability of any of the pharmacokinetic parameters. Tlag was longer, whereas Vd/F and ke/F were lower in aged compared to adult animals; in female aged dogs ke/F was lower than in male aged dogs; however, the differences were of low magnitude. Different disposition of cephalexin may be expected in aged dogs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Concentration versus time profiles of cephalexin. Symbols represent the observed data for two representative animals studied in two occasions: green line, individual estimation.
Figure 2
Figure 2
Goodness of fit plots. (a) Observed versus population predicted and (b) observed versus individual predicted values. The continuous line is the identity line, (c) scatter plot of weighted residuals versus time and (d) scatter plot of weighted residuals versus predicted cephalexin concentrations.
Figure 3
Figure 3
Visual predictive check. The figure shows the 90% prediction intervals obtained by simulation using the final model. The light blue areas are the 90% confidence intervals for the median, 5th percentile, and the 90th percentile of the simulated data. Circles represent observed data.

References

    1. Drusano G. L. Antimicrobial pharmacodynamics: critical interactions of “bug and drug”. Nature Reviews Microbiology. 2004;2(4):289–300. doi: 10.1038/nrmicro862. - DOI - PubMed
    1. Toutain P. L., del Castillo J. R. E., Bousquet-Mélou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science. 2002;73(2):105–114. doi: 10.1016/S0034-5288(02)00039-5. - DOI - PubMed
    1. Dowling P. M. Geriatric pharmacology. Veterinary Clinics of North America: Small Animal Practice. 2005;35(3):557–569. doi: 10.1016/j.cvsm.2004.12.012. - DOI - PubMed
    1. McLean A. J., le Couteur D. G. Aging biology and geriatric clinical pharmacology. Pharmacological Reviews. 2004;56(2):163–184. doi: 10.1124/pr.56.2.4. - DOI - PubMed
    1. Modric S., Martinez M. Patient variation in veterinary medicine—Part II: influence of physiological variables. Journal of Veterinary Pharmacology and Therapeutics. 2011;34(3):209–223. doi: 10.1111/j.1365-2885.2010.01249.x. - DOI - PubMed

LinkOut - more resources